Tali YaronEldar - Rosetta Genomics External Independent Director

Director

Ms. Tali YaronEldar is External Independent Director of the company since February 2007. Since January 2013 Ms. YaronEldar has served as founder of her own private practice. Between March 2007 and December 2012 Ms. YaronEldar had been a partner with the law firm of Tadmor Co. From January 2004 to March 2007 she was a partner at the law firm of Cohen YaronEldar Co. From January 2004 to January 2008 Ms. YaronEldar served as the Chief Executive Officer of Arazim Investment Company She has also served in a variety of public positions including as the Chief Legal Advisor of the Customs and V.A.T department of the Finance Ministry of the State of Israel from 1998 to 2001 and as the Commissioner of Income Tax and Real Property Tax Authority of the State of Israel from 2002 to 2004 since 2007.
Age 50
Tenure 17 years
Professional MarksMBA
Phone972 73 222 0700
Webhttp://www.rosettagx.com
YaronEldar holds an M.B.A. specializing in finance and an LL.M. from Tel Aviv University and is a member of the Israeli Bar Association.

Rosetta Genomics Management Efficiency

The company has return on total asset (ROA) of (60.19) % which means that it has lost $60.19 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (137.95) %, meaning that it created substantial loss on money invested by shareholders. Rosetta Genomics' management efficiency ratios could be used to measure how well Rosetta Genomics manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 2.45 M in liabilities with Debt to Equity (D/E) ratio of 222.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Rosetta Genomics has a current ratio of 2.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Rosetta Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, Rosetta Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rosetta Genomics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rosetta to invest in growth at high rates of return. When we think about Rosetta Genomics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Kenichi NagaiNH Foods
N/A
Hilda OchoaBrillembourgCementos Pacasmayo SAA
74
David TooleLifevantage
60
Juan VazquezCementos Pacasmayo SAA
N/A
William LaceyParker Hannifin
55
Gianfranco ZunigaCementos Pacasmayo SAA
N/A
Mark PetrarcaTopbuild Corp
57
Masashi KataokaNH Foods
N/A
Shuji OhkosoNH Foods
N/A
Hitoshi YaoNH Foods
N/A
Thomas WilliamsChart Industries
59
Jason AdelmanTrio Tech International
50
Joe DavisNatural Alternatives Internatio
83
Carl CamdenTopbuild Corp
64
Kenya MaruyamaNH Foods
N/A
Yasuko KonoNH Foods
61
Kohei AkiyamaNH Foods
N/A
Alan DunnNatural Alternatives Internatio
62
Marco GarciaCementos Pacasmayo SAA
60
Richard HorowitzTrio Tech International
78
Fumio MaedaNH Foods
58
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel. Rosetta Genomics operates under Diagnostics Research classification in USA and traded on Nasdaq Capital Markets. It employs 86 people. Rosetta Genomics (ROSG) is traded on NASDAQ Exchange in USA and employs 86 people.

Management Performance

Rosetta Genomics Leadership Team

Elected by the shareholders, the Rosetta Genomics' board of directors comprises two types of representatives: Rosetta Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rosetta. The board's role is to monitor Rosetta Genomics' management team and ensure that shareholders' interests are well served. Rosetta Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rosetta Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
David Sidransky, Independent Director
Kenneth Berlin, CEO and Pres
Anne Fields, IR Contact Officer
Joshua Rosensweig, Director
Dganit Bar, Chief Scientific Officer
Brian Markison, Chairman, Observer To Board of Directors and Member of Nominating and Corporate Governance Committee
Douglas Sites, Executive Vice President - Sales and Marketing
Tal YaronEldar, Independent Director
Eti Meiri, Vice President - Research
Robert Wassman, Chief Medical Officer
Oded Biran, General Counsel
Roy Davis, Director
Yitzhak Peterburg, Director
Kevin Watson, Director, Reimbursement-Managed Care
Ron Kalfus, CFO
Gerald Dogon, External Independent Director
Tali YaronEldar, External Independent Director

Rosetta Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rosetta Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Consideration for investing in Rosetta Stock

If you are still planning to invest in Rosetta Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rosetta Genomics' history and understand the potential risks before investing.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Bonds Directory
Find actively traded corporate debentures issued by US companies
CEOs Directory
Screen CEOs from public companies around the world
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA